The Sputnik Light vaccine (first compound of the Sputnik V vaccine), administered alone has demonstrated 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60. Sputnik Light has demonstrated superior efficacy compared with some two-shot vaccines, which have shown a major decline in efficacy against the Delta variant to less than 50% five months after injection.

Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) and Gamaleya National Research Center of Epidemiology and Microbiology announced the results of an efficacy analysis of the one-shot Sputnik Light vaccine against infection from the Delta variant of coronavirus.

Gamaleya Center has submitted an article analyzing the efficacy of the Sputnik Light vaccine against the Delta variant to the medRxiv preprint server for health sciences for publication this week.

The analysis was conducted based on data from 28,000 participants who had received a single dose of Sputnik Light, compared with a control group of 5.6 million individuals who were not vaccinated. The data used in the study was collected in July 2021 in Moscow.

A one-shot vaccination regimen of Sputnik Light has several key advantages, including ease of administering the vaccine, monitoring and a more flexible re-vaccination schedule when used as a booster.

Efficacy of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization.

The Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V – the world's first registered vaccine against coronavirus.

The heterogeneous boosting approach (a "vaccine cocktail" using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V. This approach was proven to be successful in creating a longer and more durable immunity against coronavirus. RDIF initiated partnerships with other vaccine producers to conduct joint studies on the combination of the first component of Sputnik V with other vaccines.